Welcome to our dedicated page for Accendra Health SEC filings (Ticker: ACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accendra Health, Inc. (NYSE: ACH) SEC filings page on Stock Titan is intended to provide access to the company’s regulatory disclosures once they are available from the SEC’s EDGAR system. While no specific filings are listed in the provided data, this page is designed to surface documents that explain how Accendra Health describes its business, risks and financial condition in formal reports.
Accendra Health states that it is a nationwide provider of products, technology and services that support health beyond the hospital, focusing on chronic and complex health conditions. When available, annual reports on Form 10-K and quarterly reports on Form 10-Q can offer detailed discussion of these activities, including segment descriptions, risk factors and management’s analysis of operations related to areas such as diabetes, sleep health, wound care, respiratory care, urology and ostomy.
Stock Titan enhances these filings with AI-powered summaries that highlight key themes, helping readers understand long, technical documents more efficiently. As Accendra Health’s filings appear, users will be able to review:
• Annual reports (Form 10-K) with AI-generated overviews of the company’s business description and risk disclosures.
• Quarterly reports (Form 10-Q) summarizing operational updates and changes in the business.
• Current reports (Form 8-K) that may cover significant events, such as corporate transactions or changes in strategy.
• Insider transaction reports (Form 4), once filed, to track reported purchases and sales by directors and officers.
Filings are updated in real time as they are released by the SEC, and AI summaries aim to clarify complex sections without altering the underlying content. This allows investors and researchers to quickly identify the portions of Accendra Health’s disclosures that relate to its focus on health beyond the hospital and support for chronic and complex conditions.
Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ granted EVP, General Counsel & Corporate Secretary Heath H. Galloway 61,437 shares of Common Stock as a restricted stock award. The grant carries no purchase price and vests one-third per year over three years. Following this compensation award, Galloway directly holds 178,441 Common Stock shares. This is a non-market, equity-based compensation grant rather than an open-market purchase or sale, so it reflects long-term incentive alignment more than a trading view on the stock.
Accendra Health, Inc. outlines a major reshaping of its business and key risks. The company completed the sale of its Products & Healthcare Services business for $375 million in cash, retaining a 5% equity interest, which leaves it as a smaller, single-segment home healthcare provider.
Management highlights heavy reliance on a few commercial and government payors. One large commercial payor is terminating contracts that represented $322 million, or 12% of 2025 net revenue, including nearly all capitation revenue, creating meaningful earnings and liquidity risk if not replaced or offset.
The filing stresses competitive pressures, supplier concentration, cybersecurity threats, inflation, and reimbursement uncertainty from Medicare, Medicaid and private payors. It also discusses extensive regulatory exposure, including privacy, fraud and abuse, environmental and antitrust rules, and notes Apria’s prior False Claims Act settlement and ongoing Corporate Integrity Agreement obligations through 2026.
Accendra Health, Inc. reported fourth-quarter and full-year 2025 results that reflect its shift to a standalone home-based care business after completing the sale of its Products & Healthcare Services business on December 31, 2025.
From continuing operations, net revenue rose to $708.967 million in Q4 2025 from $695.023 million a year earlier, with Q4 operating income improving to $20.9 million from a loss of $272.7 million. For 2025, continuing net revenue grew to $2.762 billion from $2.680 billion, and adjusted EBITDA was $374.847 million versus $370.515 million in 2024.
Despite better underlying performance, the company recorded a substantial full-year net loss of $1.1006 billion, driven largely by a $997.960 million loss from discontinued operations and an $80 million transaction breakage fee related to a terminated acquisition. Cash and cash equivalents increased markedly to $281.989 million at December 31, 2025, and net debt declined to $1.768 billion, while total equity moved to a deficit position. Management highlighted strong cash flow, ongoing cost controls and balance sheet optimization as it completes separation from Owens & Minor and focuses on sustainable growth.
Accendra Health Inc. received a Schedule 13G from Charles Schwab Investment Management Inc. showing a significant institutional position in its common stock. Charles Schwab Investment Management reports beneficial ownership of 4,057,056 shares, representing 5.24% of the outstanding common stock as of the triggering date.
The filing states that Schwab has sole voting and sole dispositive power over all 4,057,056 shares, with no shared voting or dispositive authority. Schwab certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Accendra Health.